Visual Assessment Versus Quantitative Assessment of 11C-PIB PET and 18F-FDG PET for Detection of Alzheimer's Disease

Ng, Serena; Villemagne, Victor L.; Berlangieri, Salvatore U; Lee, Sze-Ting; Cherk, Martin H; Gong, Sylvia; Ackermann, Uwe; Saunder, Timothy; Tochon-Danguy, Henri; Jones, Gareth; Smith, Charmaine; O’Keefe, Graeme; Masters, Colin L.; Rowe, Christopher C.

doi:10.2967/jnumed.106.037762

Cited by 229 publications

(197 citation statements)

References 34 publications

Supporting

Mentioning

177

Contrasting

Unclassified

Order By: Relevance

“…Responders who routinely used FDG-PET assigned greater incremental diagnostic value than non-users -an added value that was perceived greater than that of CSF biomarkers. Although the association was not affected by the reading procedure ("traditional visual reading" or "quantitative tool"), a considerable amount of evidence indicates that automated quantitative tools are more accurate to detect the AD pattern of cortical hypometabolism than traditional readouts [28][29][30] and attenuate the "beginner effect" [29]. Another possible explanation is that FDG-PET requires experience to be of value, in contrast to CSF, which uses very simple cut-off values.…”

Section: Discussionmentioning

confidence: 99%

“…Although this is inevitable in the case of amyloid imaging where the only FDA-and EMA-approved procedure is structured visual rating, a number of automated or semiautomated tools are available for structural MR and FDG-PET [36][37][38][39][40]. However, despite their demonstrated superiority over visual assessments [28][29][30]41,42], these more quantitative measures are used by a minority of centers. We argue that scientific societies should engage in an active campaign to promote their use, once properly validated, in cognitively impaired patients undergoing assessment for suspected AD.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey

Bocchetta

Galluzzi

Kehoe

et al. 2014

Alzheimer's & Dementia

View full text Add to dashboard Cite

We investigated the use of Alzheimer's disease (AD) biomarkers in European Alzheimer's Disease Consortium centers and assessed their perceived usefulness for the etiologic diagnosis of mild cognitive impairment (MCI). We surveyed availability, frequency of use, and confidence in diagnostic usefulness of markers of brain amyloidosis (amyloid positron emission tomography [PET], cerebrospinal fluid [CSF] Ab42) and neurodegeneration (medial temporal atrophy [MTA] on MR, fluorodeoxyglucose positron emission tomography [FDG-PET], CSF tau). The most frequently used biomarker is visually rated MTA (75% of the 37 responders reported using it "always/ frequently") followed by CSF markers (22%), FDG-PET (16%), and amyloid-PET (3%). Only 45% of responders perceive MTA as contributing to diagnostic confidence, where the contribution was rated as "moderate". Seventy-nine percent of responders felt "very/extremely" comfortable delivering a diagnosis of MCI due to AD when both amyloid and neuronal injury biomarkers were abnormal (P , .02 versus any individual biomarker). Responders largely agreed that a combination of amyloidosis and neuronal injury biomarkers was a strongly indicative AD signature.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey

Bocchetta

Galluzzi

Kehoe

et al. 2014

Alzheimer's & Dementia

View full text Add to dashboard Cite

show abstract

“…The deposition/retention of 11 C-PiB was calculated using the method previously described by Klunk et al [21]. Data from all participants imaged by PiB-PET was used to calculate the in vivo amyloid plaque load represented by SUVR, which is defined as the ratio of the standardized uptake value in each region of interest (ROI) to that of the cerebellar cortex [22].…”

Section: Pib-pet Imagingmentioning

confidence: 99%

Long-Term Cognitive Improvement After Benfotiamine Administration in Patients with Alzheimer’s Disease

et al. 2016

View full text Add to dashboard Cite

To date, we still lack disease-modifying therapies for Alzheimer's disease (AD). Here, we report that long-term administration of benfotiamine improved the cognitive ability of patients with AD. Five patients with mild to moderate AD received oral benfotiamine (300 mg daily) over 18 months. All patients were examined by positron emission tomography with Pittsburgh compound B (PiB-PET) and exhibited positive imaging with bamyloid deposition, and three received PiB-PET imaging at follow-up. The five patients exhibited cognitive improvement as assayed by the Mini-Mental Status Examination (MMSE) with an average increase of 3.2 points at month 18 of benfotiamine administration. The three patients who received follow-up PiB-PET had a 36.7% increase in the average standardized uptake value ratio in the brain compared with that in the first scan. Importantly, the MMSE scores of these three had an average increase of 3 points during the same period. Benfotiamine significantly improved the cognitive abilities of mild to moderate AD patients independently of brain amyloid accumulation. Our study provides new insight to the development of diseasemodifying therapy.

show abstract

“…Ng et al 6 studied the inter-rater variability of 15 patients with AD and 25 cognitively normal subjects (NCs) and reported that visual agreement between 2 readers was good ( ϭ 0.56). Tolboom et al 7 studied the variability of 20 patients with AD and 20 NCs and reported that agreement between 2 readers was moderate ( ϭ 0.56).…”

mentioning

confidence: 99%

Visual-Statistical Interpretation of 18F-FDG-PET Images for Characteristic Alzheimer Patterns in a Multicenter Study: Inter-Rater Concordance and Relationship to Automated Quantitative Evaluation

Yamane

Ikari

Nishio

et al. 2013

American Journal of Neuroradiology

View full text Add to dashboard Cite

show abstract

Visual Assessment Versus Quantitative Assessment of 11C-PIB PET and 18F-FDG PET for Detection of Alzheimer's Disease

Cited by 229 publications

References 34 publications

The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey

The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey

Long-Term Cognitive Improvement After Benfotiamine Administration in Patients with Alzheimer’s Disease

Visual-Statistical Interpretation of 18F-FDG-PET Images for Characteristic Alzheimer Patterns in a Multicenter Study: Inter-Rater Concordance and Relationship to Automated Quantitative Evaluation

Contact Info

Product

Resources

About